Objective: To compare the incidence of serious gastrointestinal (GI) complications and associated medical costs in a population with either osteoarthritis (OA) or rheumatoid arthritis (RA) enrolled in Medicare plans with celecoxib formulary restrictions versus plans without such restrictions.
Methods: This study was a retrospective cohort analysis of Medicare members in plans with and without celecoxib restrictions. Members diagnosed with OA or RA were identified and followed for 1 year.
Results: The restricted group had higher levels of nonselective nonsteroidal anti-inflammatory drug use (51% vs 40%, p <.001), and celecoxib use was double in the unrestricted group (16% vs 8%, p <.001). The incidence of a serious GI complication was slightly higher in the restricted group (5.4% vs 4.6%, P <.001). The adjusted mean serious GI complication-related cost for the restricted group was more than 15 times higher than that for the nonrestricted group ($1559 [95% confidence interval (CI) $1341-$1811] vs $101 [95% CI $87-$117]), adjusted mean arthritis-related medical costs were $5733 per year (95% CI $5097-$6448) for the restricted group and $3170 (95% CI $2816-$3569) for the unrestricted group.
Conclusions: The restricted group had significantly less use of celecoxib, indicating that restriction was effective at reducing celecoxib utilization. Although limitations exist when comparing populations from different health plans, and the underlying causes of serious GI complications are multifactorial, the restricted group had a higher incidence of serious GI complications and higher costs related to serious GI complications and arthritis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
BMJ
September 2024
Department of Neurology, Danish Headache Centre, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Objective: To compare all licensed drug interventions as oral monotherapy for the acute treatment of migraine episodes in adults.
Design: Systematic review and network meta-analysis.
Data Sources: Cochrane Central Register of Controlled Trials, Medline, Embase, ClinicalTrials.
Systematic review and network meta-analysis of different non-steroidal anti-inflammatory drugs for juvenile idiopathic arthritis.
World J Clin Cases
April 2024
College of Medicine, Jingchu University of Technology Jingmen, Jingmen 448000, Hubei Province, China.
Background: Various non-steroidal anti-inflammatory drugs (NSAIDs) have been used for juvenile idiopathic arthritis (JIA). However, the optimal method for JIA has not yet been developed.
Aim: To perform a systematic review and network meta-analysis to determine the optimal instructions.
Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction.
Biochem Pharmacol
June 2024
Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Gyeonggi, Republic of Korea; Institute of Medical Science, Ajou University School of Medicine, Suwon, Gyeonggi, Republic of Korea. Electronic address:
Gain-of-function mutation in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) is a significant factor in head and neck cancer (HNC). Patients with HNC harboring PIK3CA mutations receive therapeutic benefits from the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, the molecular mechanisms underlying these effects remain unknown.
View Article and Find Full Text PDFUnveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma.
Cell Death Differ
May 2024
Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Article Synopsis
- Esophageal squamous cell carcinoma (ESCC) shows increased activation of the methionine cycle, which is linked to poorer patient survival and drives cell proliferation through S-adenosyl-methionine (SAM) production.
- The study reveals that methionine influences gene expression by enhancing METTL3-mediated RNA methylation, particularly affecting the expression of NR4A2, a gene that promotes ESCC growth and worsens patient outcomes.
- Celecoxib is identified as a potential new treatment for ESCC by inhibiting NR4A2, suggesting that targeting the methionine cycle could be a more effective approach than restricting methionine intake itself.*
Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders.
Saudi Med J
May 2023
From the Department of Medicine, Faculty of Medicine, Umm AlQura University, Makkah, Kingdom of Saudi Arabia.
Objectives: To examine the potential therapeutic effects of ursodeoxycholic acid (UDCA) on diseases of the esophagus, stomach, and duodenum.
Methods: A search was conducted using EBSCO, Medline, PubMed, Google Scholar and Web of Science as well as international guidelines using MESH terms for treatment of UDCA for diseases of the upper gastrointestinal disorders in adult humans without regard to publication language or date restrictions.
Results: A total of 256 articles and 22 guidelines were initially identified, and 221 were excluded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!